Tularik
Executive Summary
South San Francisco, Calif.-based firm will collaborate with the Japanese company Yamanouchi Pharmaceutical on research relating to the regulation of genes involved in inflammation. Under the agreement announced Nov. 4, the companies are seeking to discover and ultimately develop unique small molecules that act by modulating the activity of transcription factors associated with a variety of inflammatory diseases. The collaboration combines Tularik's transcription factor research expertise and both companies' drug screening and medicinal chemistry capabilities. Terms of the agreement were not disclosed.